Cystic fibrosis: tobramycin inhalation: 24 month predicted versus actual analysis
Page last updated: 6 March 2015
Drug utilisation sub-committee (DUSC)
October 2014
Abstract
Purpose
To examine the utilisation of tobramycin solution for inhalation (TSI) in the 24 months since PBS listing on 1 October 2011. TSI is listed for the management of a proven Pseudomonas aeruginosa infection in cystic fibrosis patients. The DUSC regularly examines utilisation of PBS items when there is at least 24 months of prescription data available and where the DUSC or the PBAC has requested analysis of utilisation.
Date of listing on PBS
1 October 2011.
Data Source / methodology
The Department of Human Services (Medicare) Supplied Prescriptions Database was used for the analyses. The analyses are based on the date of prescription supply unless otherwise stated.
Key Findings
- 1,213 and 1,332 patients received TSI in the first and second year of PBS listing. The total number of patients treated with tobramycin in the second year of listing was close to what was predicted.
- The number of TSI packs supplied and Government expenditure was lower than expected. This appears to be due to patients aged 10 years and over receiving fewer prescriptions per year than expected.
